Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBCV in HR+ Breast Cancer
NCT03804944Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, Flt3 ligand in breast cancer, sponsored by Weill Cornell Medicine. Started Mar 2020; status: recruiting.
02
Drugs
pembrolizumabFlt3 ligand
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03804944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804944.